The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-analysis

Cancer

Volumn 118, Issue 7, 2012, Pages 1764-1773

  Kim, Tae Hyuk ^a   Park, Young Joo ^a,b   Lim, Jung Ah ^a   Ahn, Hwa Young ^b   Lee, Eun Kyung ^c   Lee, You Jin ^c   Kim, Kyung Won ^d   Hahn, Seo Kyung ^e   Youn, Yeo Kyu ^a   Kim, Kwang Hyun ^a   Cho, Bo Youn ^f   Park, Do Joon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c National Cancer Center   (South Korea)

^d Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Chung Ang University College of Medicine   (South Korea)

Author keywords

BRAF; Meta analysis; Papillary; Papillary thyroid carcinoma; Thyroid cancer; V600E

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; RADIOACTIVE IODINE; VALINE;

ARTICLE; BRAF GENE; CANCER INVASION; CANCER STAGING; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR ABLATION; WILD TYPE;

ADULT; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; THYROID NEOPLASMS;

EID: 84863385520     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26500     Document Type: Article

References (52)

1. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975-2005/. Accessed on December 24, 2010.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115: 3801-3807.
3. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404.
4. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-3562. (Pubitemid 27509336)
5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428. (Pubitemid 24345593)
6. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012-1021. (Pubitemid 28401936)
7. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321:86-93.
8. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627. (Pubitemid 36553510)
9. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762. (Pubitemid 350294294)
10. Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett. 2007;28:351-359. (Pubitemid 47577711)
11. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004;61:239-243. (Pubitemid 39093120)
12. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63:588-593. (Pubitemid 41626756)
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012. (Pubitemid 30214957)
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
16. Abrosimov A, Saenko V, Rogounovitch T, et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer. 2007;120:196-200. (Pubitemid 44901936)
17. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008;93:611-618. (Pubitemid 351240838)
18. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222. (Pubitemid 43740191)
19. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840-2843. (Pubitemid 47037399)
20. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
21. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15:191-205. (Pubitemid 351449739)
22. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008;28: 305-308. (Pubitemid 351362917)
23. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612-1617.
24. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89-97.
25. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667-3670. (Pubitemid 44402153)
26. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246: 466-470. (Pubitemid 47312140)
27. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006;244:799-804. (Pubitemid 44629955)
28. Kim KH, Suh KS, Kang DW, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int. 2005;55:540-545.
29. Lee JH, Lee ES, Kim YS, Won NH, Chae YS. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38:201-204. (Pubitemid 43879713)
30. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf). 2005;63:461-466.
31. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92:4085-4090. (Pubitemid 350074715)
32. Musholt TJ, Schonefeld S, Schwarz CH, et al. Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES Vienna presentation. Langenbecks Arch Surg. 2010;395: 877-883.
33. Nakayama H, Yoshida A, Nakamura Y, et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res. 2007;27:3645-3649. (Pubitemid 47607514)
34. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397. (Pubitemid 37153748)
35. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 2009;115:972-980.
36. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006;13:257-269.
37. Rivera M, Ricarte-Filho J, Tuttle RM, et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid. 2010;20:1085-1093.
38. Sykorova V, Dvorakova S, Ryska A, et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest. 2010;33:318-324.
39. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373-6379. (Pubitemid 41759286)
40. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567. (Pubitemid 36951030)
41. Xing M. The lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution. Endocr J. 2009;56:305-306; author reply 307-308.
42. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723-5729. (Pubitemid 41415482)
43. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070-1077.
44. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a metaanalysis. Cancer. 2007;110:38-46.
45. Nucera C, Lawler J, Parangi S. BRAFV600E and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011;71:2417-2422.
46. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
47. Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 2011;30:3153-3162.
48. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010;107:10649-10654.
49. Wang Y, Ji M, Wang W, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer. 2008;15:183-190. (Pubitemid 351449738)
50. Nucera C, Nehs MA, Nagarkatti SS, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16:296-309.
51. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146:1215-1223.
52. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and metaanalysis. Lancet. 2009;373:1773-1779.